World Bulletin of Public Health (WBPH)
Available Online at: https://www.scholarexpress.net
Volume-53 December 2025
ISSN: 2749-3644

BREAST SARCOMA

PhD Orifjon Absamatillaevich Talipov
Department of Oncology,
Pediatric Oncology, and Palliative CareSenior Lecturer,

Article history:

Received: September 14th 2025
Accepted: October 11th 2025

Abstract:

Breast sarcoma is a rare and aggressive malignancy arising from the mesenchymal tissues of the breast. Unlike the more common epithelial breast carcinomas, sarcomas demonstrate distinct biological behavior, clinical presentation, and treatment requirements. Early diagnosis and accurate histopathological classification are essential for effective management. This review provides an overview of the epidemiology, clinical features, histological subtypes, and therapeutic approaches for breast sarcoma.

Keywords: Breast sarcoma, mesenchymal tumor, histopathology, treatment, prognosis

INTRODUCTION:

Breast sarcomas are uncommon tumors, accounting for less than 1% of all breast malignancies. They originate from connective tissues rather than epithelial cells, which distinguishes them from the more prevalent breast carcinomas. The clinical presentation often includes a rapidly growing, painless mass, and imaging findings can be non-specific, making diagnosis challenging. Histopathological examination remains the gold standard for subtype identification, which is critical for prognosis and treatment planning. Due to their aggressive nature and high risk of recurrence, management typically involves surgical excision with negative margins, and in selected cases, adjuvant radiotherapy or chemotherapy may be indicated. Understanding the unique characteristics of breast sarcoma is vital for optimizing patient outcomes and guiding future research.

Breast sarcomas are a heterogeneous group of tumors originating from the mesenchymal components of the breast, including fibrous, vascular, and adipose tissues. They differ significantly from epithelial breast carcinomas in terms of pathogenesis, biological behavior, and response to therapy. The rarity of these tumors contributes to limited clinical experience and evidence-based treatment guidelines.

The most common histological subtypes of breast sarcoma include angiosarcoma, fibrosarcoma, liposarcoma, and malignant phyllodes tumor. Angiosarcomas are highly aggressive vascular tumors that often develop following prior radiation therapy, while fibrosarcomas and liposarcomas arise from fibrous and fatty tissues, respectively. Malignant phyllodes tumors are biphasic neoplasms containing both epithelial and stromal components, and they have a variable potential for local recurrence and distant metastasis.

Surgical excision with negative margins remains the cornerstone of treatment for all breast sarcoma subtypes. Unlike breast carcinomas, axillary lymph node dissection is generally not indicated, as nodal involvement is rare. Adjuvant radiotherapy may be considered for high-grade tumors or cases with close or positive margins to reduce local recurrence. Chemotherapy is reserved for metastatic or unresectable disease, although its efficacy is limited and often depends on the histological subtype.Prognosis in breast sarcoma is largely determined by tumor size, histological grade, margin status, and the presence of metastases at diagnosis. High-grade tumors and angiosarcomas are associated with poorer outcomes, whereas complete surgical excision of low-grade lesions offers the best chance for long-term survival. Regular follow-up with imaging is essential due to the risk of local recurrence and distant spread, particularly to the lungs.Emerging research is exploring the molecular and genetic characteristics of breast sarcomas to identify potential therapeutic targets. Advances in targeted therapies and immunotherapy hold promise for improving outcomes in aggressive and metastatic cases, although large-scale clinical trials are limited due to the rarity of the disease.

Recent studies have highlighted the importance of early detection and accurate histopathological classification in improving patient outcomes. Imaging modalities such as mammography, ultrasound, and magnetic resonance imaging (MRI) can assist in evaluating tumor size, margins, and vascularity, but definitive diagnosis requires biopsy and immunohistochemical analysis. Markers such as CD34, vimentin, and Ki-67 help in distinguishing sarcoma subtypes and assessing proliferative activity.In addition to surgical management, a multidisciplinary approach is essential for optimal care. Collaboration between surgical oncologists, medical oncologists, radiologists, and pathologists ensures

World Bulletin of Public Health (WBPH)
Available Online at: https://www.scholarexpress.net
Volume-53 December 2025
ISSN: 2749-3644

accurate diagnosis, appropriate treatment planning, and comprehensive follow-up. Personalized treatment strategies based on tumor subtype, grade, and patient factors are crucial for reducing recurrence risk and improving survival rates.

Furthermore, research into the molecular pathways involved in sarcoma development is expanding therapeutic possibilities. For example, targeting angiogenesis in angiosarcomas or exploring novel cytotoxic agents for high-grade tumors could enhance treatment efficacy. Participation in clinical trials is encouraged whenever feasible, as it provides access to emerging therapies and contributes to the collective understanding of this rare malignancy.Breast sarcoma management requires a combination of precise surgical intervention, careful pathological evaluation, and consideration of adjuvant therapies to achieve the best possible outcomes. The rarity and biological diversity of these tumors underscore the need for ongoing research and individualized patient care.

Long-term follow-up is critical for patients with breast sarcoma due to the high risk of local recurrence and distant metastasis, particularly in aggressive subtypes such as angiosarcoma and high-grade malignant phyllodes tumors. Recurrences often occur within the first few years after treatment, emphasizing the importance of regular clinical examinations and imaging studies. Patient education regarding symptom monitoring and prompt reporting of new masses or changes is also a key component of post-treatment care.Understanding the epidemiological and risk factors associated with breast sarcoma is essential for preventive strategies. Radiation exposure, prior breast cancer treatment, and certain genetic predispositions have been identified as contributing factors for some sarcoma subtypes. Awareness of these factors can aid in early detection and risk stratification, potentially improving outcomes through timely intervention.Although breast sarcomas remain rare, ongoing advances in molecular biology, imaging, and surgical techniques are progressively enhancing diagnosis, treatment, and prognosis. Multidisciplinary management, tailored to tumor subtype and patient characteristics, remains the cornerstone of effective care, ensuring optimal survival and quality of life for affected individuals.

CONCLUSION.

Breast sarcoma is a rare and aggressive malignancy with distinct biological and clinical characteristics compared to epithelial breast cancers. Early diagnosis, accurate histopathological classification, and complete surgical excision with negative margins are critical for optimal management. The role of adjuvant radiotherapy and chemotherapy depends on tumor grade, size, and subtype, with multidisciplinary care being essential for improving outcomes. Advances in molecular profiling, targeted therapies, and immunotherapy offer promising avenues for treatment, particularly in high-grade or metastatic cases. Continuous research, early detection, and individualized patient management remain the cornerstones for enhancing prognosis and quality of life in patients with breast sarcoma.

REFERENCES.

1. Adem, C., Reynolds, C., Ingle, J.N., & Nascimento, A.G. (2004). Primary breast sarcoma: Clinicopathologic series from the Mayo Clinic and review of the literature. British Journal of Cancer, 91(2), 237–241.
2. Blanchard, D.K., Chen, Y., Sainani, K., & Feig, B.W. (2003). Primary breast sarcoma in the surveillance, epidemiology, and end results database. Surgery, 134(4), 736–741.
3. McGowan, T.S., et al. (2000). Primary sarcomas of the breast: The Mayo Clinic experience. Cancer, 88(7), 1426–1435.
4. Rosen, P.P. (2009). Rosen's Breast Pathology (3rd ed.). Philadelphia: Lippincott Williams & Wilkins.
5. Gutman, H., & Heshmati, H.M. (1994). Sarcomas of the breast: An analysis of 20 cases. American Journal of Surgery, 167(6), 599–602.